Clinical management of breast cancer currently employs diagnostic patient evaluations aimed at designing more “personalized” therapeutic modalities including tamoxifen for the treatment of estrogen receptor positive (ER+) disease, or trastuzumab for human epidermal growth factor receptor-2 (HER2) positive disease. Here, ESR1 is linked to breast carcinoma.